The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.
The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
The FDA has approved an implantable neurostimulation system designed for the treatment of intractable chronic low back pain associated with multifidus muscle dysfunction.
The US Food and Drug Administration has approved the marketing of the first video game-based digital therapeutic device for the treatment of children aged 8 to 12 years with attention deficit hyperactivity...
